On February 13, 2026, Neo Ivy Capital Management disclosed a new position in Dolby Laboratories (NYSE:DLB), acquiring 117,964 shares in a trade estimated at $7.58 million. What happened Neo Ivy Capital Management reported in a February 13, 2026, SEC filing that it established a new stake in Dolby Laboratories, acquiring 117,964 shares. The estimated transaction value was $7.58 million. What else to know This new position in DLB represents 1.2% of Neo Ivy’s reportable U.S. equity AUM after the fourth q ...

Core Insights - Dolby Laboratories reported a notable insider sale by President and CEO Kevin J. Yeaman, who sold 36,699 shares amid a year of declining share prices [1][9] - The company experienced a revenue increase to $1.35 billion for the fiscal year ending September 26, 2025, but net income fell to $255 million due to rising costs [10] - Dolby forecasts fiscal 2026 sales between $1.39 billion to $1.44 billion, indicating modest year-over-year growth [11] Transaction Summary - The transaction involved the exercise of options and immediate sale of 36,699 shares, valued at approximately $2.5 million [2] - Post-transaction, Yeaman retains direct ownership of 127,735 shares, valued at around $8.5 million [2] - The sale occurred at a weighted average price of $66.91 per share, consistent with the market close on the transaction date [6] Company Overview - Dolby Laboratories specializes in audio and imaging technologies, including Dolby Atmos and Dolby Vision, and generates revenue primarily through technology licensing and hardware sales [7][8] - The company serves a diverse customer base, including film studios, content creators, and broadcasters, leveraging a licensing-driven business model [8] Market Context - The stock price had declined 12.41% over the preceding year, with a recent 52-week low of $64.02 [6][9] - The current price-to-earnings ratio is at a multi-year low, suggesting a potential opportunity for investors [12]